Study wrapper · #1041
Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study.
Editor's note
This is a prospective observational cohort, not a randomized trial, so unmeasured differences between the semaglutide and control groups could account for part of the association. The reported cognitive improvements and lower rate of progression to dementia are notable signals, but the authors themselves call for randomized trials to confirm them. Read the results as hypothesis-generating for semaglutide's studied neurocognitive effects.
Plain-language abstract
In this 24-month observational study of older adults with type 2 diabetes and mild cognitive impairment, those taking semaglutide showed improved cognitive test scores and were less likely to progress to dementia than a comparison group. Because this was an observational study rather than a randomized trial, the findings are suggestive rather than definitive.